The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The U.S. Food and Drug Administration approved an HIV prevention medication that has been proven highly effective in clinical ...

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthrou ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...